Cipla
Cipla is a peptide manufacturer based in India (Mumbai). Direct manufacturer. Founded 1935. Holds US DMFs for difelikefalin, icatibant, terlipressin API.
Listing reviewed October 2026.
About Cipla
Mumbai-based pharmaceutical group, founded in 1935, making generic medicines and APIs. Holds active US Drug Master Files for difelikefalin, icatibant and terlipressin API and markets icatibant injection in the US. Its Kurkumbh API site was classed VAI at its 2024 FDA inspection. The FDA warning letters below were issued to finished-dose sites, not a peptide API site.
Directory assessment: Cipla is listed as a manufacturer in the peptide supply chain, serving Asia markets from India (Mumbai). As a direct manufacturer, this supplier controls its own production process from synthesis through purification and quality control release testing. This profile lists 3 sources for reference. This supplier has a medium confidence score — verification signals are present, but the listing is newer or less documented; perform standard due diligence before engaging.
- Difelikefalin: DMF 37712 (Type II, active), submitted 2023-01-25
- Icatibant: DMF 32318 (Type II, active), submitted 2018-01-08
- Terlipressin: DMF 43499 (Type II, active), submitted 2026-04-15
DMF numbers from the FDA quarterly DMF list. A filed DMF is not FDA approval; its contents are confidential. Reviewed 2026-10-23.